GayWebSource.com – LGBTQ News And Press Release Syndication. Connecting Gay News Media Worldwide Since Nov. 2001, Over 20 Yrs Serving the Gay Community.
Submit New Post < You must use this link to submit your content manually. If you are posting on your wall or using the feedly rss feed. It stays on your wall and not into our syndication
<p>A new drug has been made available for the treatment of Chronic Hepatitis C Infection.</p>
<p>by Newsdesk | 27th January 2014</p><p></p><p>o The European Commission has granted marketing authorisation for Sovaldi® by Gilead.</p><p>o The drug can offer high cure rates of more than 90%</p><p>o Treatment useable by patients who aren’t suitable for other forms of medication.</p><p></p><p></p><p>In the UK Hepatitis C (HCV) is estimated to affect 215,000 adults and is a major cause of liver cancer and liver transplantation. Trends on HCV-related deaths in England appear to show a year on year increase with HCV-related deaths outstripping reported HIV-related deaths for the first time in 2012. </p><p></p><p>Up until now standard treatment for HCV involved treatments that last up to 48 weeks, with a peg-IFN/RBV-containing regimen, which may not be suitable for certain types of patients.</p><p></p><p>Hepatitis is a virus that can infect and damage the liver and can be transmitted in the blood, saliva, semen and vaginal fluids. </p><p></p><p>The most common method of transmission in the UK is through shared needles to inject illegal drugs, less commonly people can get HCV through unprotected sex.</p><p></p><p>The new treatment from Gilead is a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection in adults, in combination with other agents.</p><p></p><p>“Unlike many chronic diseases, hepatitis C can be cured. For many HCV patients, however, for a number of reasons, many HCV patients have not currently achieved a cure and often progress to end-stage liver disease or liver cancer,” said Dr Graham Foster, Professor of Hepatology, Queen Mary University of London. “With high cure rates across a broad range of patients and a short duration of therapy, sofosbuvir is a very welcome therapeutic advance that will increase the number of patients who can be treated and ultimately cured.”</p><p></p><p></p><p>For more information visit: <a href="http://gilead.com/">gilead.com </a></p><p></p><p>If you've got a sexual health query please visit: <a href="http://noexcuseproject.co.uk/">noexcuseproject.co.uk</a></p><p>
</p>
A new drug has been made available for the treatment of Chronic Hepatitis C Infection.
by Newsdesk | 27th January 2014
o The European Commission has granted marketing authorisation for Sovaldi® by Gilead.
o The drug can offer high cure rates of more than 90%
o Treatment useable by patients who aren’t suitable for other forms of medication.
In the UK Hepatitis C (HCV) is estimated to affect 215,000 adults and is a major cause of liver cancer and liver transplantation. Trends on HCV-related deaths in England appear to show a year on year increase with HCV-related deaths outstripping reported HIV-related deaths for the first time in 2012.
Up until now standard treatment for HCV involved treatments that last up to 48 weeks, with a peg-IFN/RBV-containing regimen, which may not be suitable for certain types of patients.
Hepatitis is a virus that can infect and damage the liver and can be transmitted in the blood, saliva, semen and vaginal fluids.
The most common method of transmission in the UK is through shared needles to inject illegal drugs, less commonly people can get HCV through unprotected sex.
The new treatment from Gilead is a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection in adults, in combination with other agents.
“Unlike many chronic diseases, hepatitis C can be cured. For many HCV patients, however, for a number of reasons, many HCV patients have not currently achieved a cure and often progress to end-stage liver disease or liver cancer,” said Dr Graham Foster, Professor of Hepatology, Queen Mary University of London. “With high cure rates across a broad range of patients and a short duration of therapy, sofosbuvir is a very welcome therapeutic advance that will increase the number of patients who can be treated and ultimately cured.”
New Members: If You Just Created A New Account, Please Upload A Logo or A Photo To Represent You or Your Publication. All new accounts must have an avatar pic. We will not approve your account until your profile has been competed. You will not have full access of the site until your account is approved. We require this to help keep out spam accounts. To edit your profile, click on your name in the top right corner of the site and follow the profile links. If Your Account Has Been Recently Migrated Please Click = > Here.
More Stories
1 Song for Equality and Peace by Craymo
Gay Film Weekend Banned In 1,100 Catholic Owned Cinemas In Italy
Big Brother’s Aaron Frew Leaves Nothing To The Imagination With Completely Naked Shot